Thoratec Corporation has received FDA approval for its PMA (PreMarket Approval) application, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) as a bridge-to-transplantation (BTT) in patients suffering from advanced-stage heart failure. The system supports the weakened heart of younger adults who are at risk of dying while awaiting a heart transplant.